These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33460336)

  • 1. Efficacy evaluation of anticancer agents in single-arm clinical trials: analysis of review reports from Pharmaceuticals and Medical Devices Agency.
    Hatogai K; Kato Y; Hirase C
    Acta Oncol; 2021 Feb; 60(2):143-148. PubMed ID: 33460336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan.
    Maeda H; Shingai R; Takeda K; Hara A; Murai Y; Ofuchi M
    JAMA Netw Open; 2023 Apr; 6(4):e238875. PubMed ID: 37115550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
    Hilal T; Sonbol MB; Prasad V
    JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-arm trials for US Food and Drug Administration cancer drug approvals: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.
    Nierengarten MB
    Cancer; 2023 Jun; 129(11):1626. PubMed ID: 37158643
    [No Abstract]   [Full Text] [Related]  

  • 9. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
    Kesselheim AS; Myers JA; Avorn J
    JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021.
    Kandemir EA
    J Oncol Pharm Pract; 2023 Jan; 29(1):191-207. PubMed ID: 35793068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
    Downing NS; Aminawung JA; Shah ND; Krumholz HM; Ross JS
    JAMA; 2014 Jan 22-29; 311(4):368-77. PubMed ID: 24449315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies.
    Ladanie A; Speich B; Briel M; Sclafani F; Bucher HC; Agarwal A; Ioannidis JPA; Pereira TV; Kasenda B; Hemkens LG
    J Clin Epidemiol; 2019 Oct; 114():49-59. PubMed ID: 31158450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
    Mitra-Majumdar M; Gunter SJ; Kesselheim AS; Brown BL; Joyce KW; Ross M; Pham C; Avorn J; Darrow JJ
    JAMA Netw Open; 2022 May; 5(5):e2212454. PubMed ID: 35579897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022.
    Mousavi I; Olivier T; Prasad V
    JAMA Netw Open; 2022 Jun; 5(6):e2216058. PubMed ID: 35687338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021.
    Huang Y; Xiong W; Zhao J; Li W; Ma L; Wu H
    J Clin Epidemiol; 2023 May; 157():74-82. PubMed ID: 36905971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.
    Hilal T; Gonzalez-Velez M; Prasad V
    JAMA Intern Med; 2020 Aug; 180(8):1108-1115. PubMed ID: 32539071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designs.
    Hirai T; Suzuki A; Yamori T; Matsuura M
    Invest New Drugs; 2022 Feb; 40(1):142-150. PubMed ID: 34417913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review.
    Wang B; Kesselheim AS
    BMJ; 2015 Sep; 351():h4679. PubMed ID: 26400844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
    Yamashita K; Kaneko M; Narukawa M
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.